Home > Drugs A – Z > Piperacillin/Tazobactam (By injection)

Piperacillin/Tazobactam (By injection)

Treats infections. The medicine contains a penicillin antibiotic.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Piperacillin and tazobactam injection is used to treat bacterial infections in many different parts of the body. Piperacillin and tazobactam combination is an antibiotic that belongs to the group of medicines known as penicillins and beta-lactamase inhibitors. It works by killing the bacteria and preventing their growth. However, this medicine will not work for colds, flu, or other virus… Read more
Brand names include
Piperacillin Sodium-Tazobactam Sodium Novaplus, PremierPro Rx Piperacillin and Tazobactam, Zosyn
Drug classes About this

What works? Research summarized

Evidence reviews

Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review

PURPOSE: The purpose of this study is to review the rationale of prolonged (ie, extended or continuous) infusion of piperacillin/tazobactam (PIP/TAZ) in critically ill patients and to perform a systematic review that compare the effectiveness of prolonged infusion with intermittent bolus of PIP/TAZ.

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis

We sought to study whether the better pharmacokinetic and pharmacodynamic (PK/PD) properties of carbapenems and piperacillin/tazobactam, when the duration of infusion is longer, were associated with lower mortality. PubMed and Scopus were searched for studies reporting on patients treated with extended (≥3 hours) or continuous (24 hours) versus short-term duration (20-60 minutes) infusions of carbapenems or piperacillin/tazobactam. Fourteen studies were included (1229 patients). Mortality was lower among patients receiving extended or continuous infusion of carbapenems or piperacillin/tazobactam compared to those receiving short-term (risk ratio [RR], 0.59; 95% confidence interval [CI], .41-.83). Patients with pneumonia who received extended or continuous infusion had lower mortality than those receiving short-term infusion (RR, 0.50; 95% CI, 0.26-0.96). Data for other specific infections were not available. The available evidence from mainly nonrandomized studies suggests that extended or continuous infusion of carbapenems or piperacillin/tazobactam was associated with lower mortality. Well-designed randomized controlled trials are warranted to confirm these findings before such approaches become widely used.

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials

The review found that ertapenem appeared to be as safe and effective as piperacillin/tazobactam for treatment of complicated infections, particularly those of mild to moderate severity. Although the search was limited, the review was generally well conducted and the authors’ conclusions appear likely to be reliable.

See all (26)

Summaries for consumers

Single‐agent antibiotic treatment for cancer patients with fever and low white blood cell counts

Cancer patients develop neutropenia, a decrease in the neutrophil subset of the white blood cells, as a result of chemotherapy. Neutropenia exposes patients to infections, mainly bacterial. Without antibiotic treatment these infections may be fatal, therefore antibiotic treatment is administered when a patient with neutropenia develops fever. The objective of this review was to compare antibiotic treatments currently recommended in consensus guidelines for the initial treatment of cancer patients with fever and neutropenia.

Antibiotic therapy for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA)‐infected or colonised non surgical wounds

Non surgical wounds include chronic skin ulcers (such as pressure sores or diabetic ulcers), burns and traumatic wounds. Methicillin‐resistant Staphylococcus aureus (MRSA) can be present in 7% to 30% of such wounds, and the MRSA may spread into the bloodstream, causing a life‐threatening illness. A proportion of the wounds in which MRSA was present show signs of infection such as redness, pain, and pus discharge. The presence of MRSA without infection is called colonisation. It is not clear whether antibiotics should be used in MRSA colonised non‐surgical wounds. The antibiotic that has to be used in MRSA‐infected wounds is also not clear. We tried to find this out by performing a thorough search of the medical literature for studies that compared different antibiotic treatments for MRSA‐infected or MRSA‐colonised non surgical wounds. We included only randomised controlled trials, as, if they are conducted properly, they provide the best information. We included all relevant randomised controlled trials irrespective of the language in which the study was reported, the year of publication, and the number of people included in them. Two review authors independently identified the trials and extracted the relevant information in order to decrease the chance of an error occurring during this process.

PubMed Health Blog...

read all...